IDH1 and astrocytoma (excluding glioblastoma): The combination of histological, immunohistochemical, and molecular findings, including IDH1, R132H mutation, MYC amplification, and the absence of 1p/19q co-deletion, aligns with the diagnosis of astrocytoma, IDH-mutant, WHO Grade 4, based on the 2021 WHO classification.